Your session is about to expire
← Back to Search
Zandelisib for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new cancer drug, Zandelisib, to see if it's more effective than standard immunochemotherapy for treating relapsed or refractory FL and MZL.
- Non-Hodgkin's Lymphoma
- Marginal Zone Lymphoma
- Follicular Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are people with the target condition being recruited for this research project?
"That is correct. The information available on clinicaltrials.gov suggests that the trial is still recruiting patients. The trial was initially posted on August 13th, 2021 and was last updated on September 22nd, 2022. The study needs to recruit 534 patients from 17 different locations."
Are there any other active trial sites for this medication in Canada?
"There are a total of 17 clinical sites conducting this trial; please choose the one nearest to your location to reduce travel time if you decide to enroll. The sites are located in Springfield, Long Beach, Cleveland, and 14 other cities."
What are the conditions that Zandelisib has been shown to be effective against?
"Zandelisib is frequently used to treat lung cancers, including small cell lung cancer (sclc), as well as thyroiditis and polyangium."
What is the efficacy of Zandelisib in treating patients?
"Zandelisib was first researched in 1993 at National Institutes of Health Clinical Center. 2190 studies have been completed to date. There are currently 1381 live trials, a large number of which are based in Springfield, Missouri."
how many people are participating in this experiment?
"That is correct. The clinical trial is listed as currently recruiting patients on clinicaltrials.gov. It was first posted on 8/13/2021 and was last edited on 9/22/2022. The study is looking for 534 patients from 17 different sites."
Is Zandelisib's safety and efficacy backed by the FDA?
"Zandelisib has received a score of 3 from our team at Power. This is because Zandelisib is in Phase 3 of clinical trials, suggesting that not only is there evidence of efficacy, but also that there is supportive data for safety from multiple rounds of testing."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger